Literature DB >> 18580869

Economic evaluation of pharmacogenetic tests.

A C Wu1, A L Fuhlbrigge.   

Abstract

Ever since the sequencing of the human genome was completed, prediction of treatment response in terms of genetic variation has been seen as an important and achievable goal. Pharmacogenetics is the study of how genetic differences affect variation in response to medication. One potential goal of pharmacogenetics is to be able to deliver "personalized medicine" by making management decisions that optimize patient health outcomes based on a patient's genetic makeup. Pharmacogenetic tests have the potential to (i) predict intended response, the goal outcome of the medication; (ii) predict unintended response to the medication, such as adverse events; (iii) titrate medication dose; and (iv) inform the development of novel therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18580869     DOI: 10.1038/clpt.2008.127

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine?

Authors:  Harry Enchin
Journal:  AMIA Annu Symp Proc       Date:  2009-11-14

Review 2.  Personalized medicine: understanding probabilities and managing expectations.

Authors:  Zachary Laksman; Allan S Detsky
Journal:  J Gen Intern Med       Date:  2010-09-28       Impact factor: 5.128

3.  Pharmacogenomics-based practice in North Cyprus: its adoption by pharmacists and their attitudes and knowledge.

Authors:  Louai Alsaloumi; Abdikarim Abdi; Özgür Tosun; Bilgen Başgut
Journal:  Int J Clin Pharm       Date:  2019-07-02

Review 4.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Authors:  Henry M Dunnenberger; Kristine R Crews; James M Hoffman; Kelly E Caudle; Ulrich Broeckel; Scott C Howard; Robert J Hunkler; Teri E Klein; William E Evans; Mary V Relling
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-02       Impact factor: 13.820

5.  Molecular therapy drives patient-centric health care paradigms.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2010-08       Impact factor: 4.689

Review 6.  Translational research in nicotine dependence.

Authors:  Jill R Turner; Allison Gold; Robert Schnoll; Julie A Blendy
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

Review 7.  Current status of pharmacogenomics testing for anti-tumor drug therapies: approaches to non-melanoma skin cancer.

Authors:  Rebecca Grealy; Lyn R Griffiths
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

8.  Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.

Authors:  Jared T Hagaman; Brent W Kinder; Mark H Eckman
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

9.  Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine.

Authors:  Katherine Bonter; Clarissa Desjardins; Nathan Currier; Jason Pun; Fredrick D Ashbury
Journal:  BMJ Open       Date:  2011-07-29       Impact factor: 2.692

10.  Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx).

Authors:  Katja Susanne Just; Michael Steffens; Jesse Joachim Swen; George P Patrinos; Henk-Jan Guchelaar; Julia Carolin Stingl
Journal:  Eur J Clin Pharmacol       Date:  2017-07-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.